Cerebral venous thrombosis.
Cerebral venous thrombosis (CVT) has an incidence of 1.32/100,000/years in high-income countries, and higher in middle- and low-income countries. CVT is more frequent in infants and children young adults and females, especially during pregnancy/puerperium. CVT are now being diagnosed with increasing frequency because of the increased awareness and higher use of magnetic resonance imaging (MR) for investigating patients with acute and subacute headaches and new onset seizures. CVT rarely present as a stroke syndrome. Their most frequent presentations are isolated headache, intracranial hypertension syndrome, seizures, a lobar syndrome and encephalopathy. The confirmation of the diagnosis of CVT relies on the demonstration of thrombi in the cerebral veins and/or sinuses by MR/MR venography or veno CT. The more frequent risk factors/associated conditions for CVT are genetic prothrombotic conditions, antiphospholipid syndrome and other acquired prothrombotic diseases, including cancer, oral contraceptives, puerperium and pregnancy, infections and trauma. The prognosis of CVT is in general favorable, as acute death rate is below 5% and only 15% of the patients remain dependent or die. Treatment in the acute phase includes management of the associated condition, anticoagulation with either low molecular weight or unfractionated heparin, treatment of intracranial hypertension, prevention of recurrent seizures and headache relief. In patients in severe condition on admission or who deteriorate despite anticoagulation, local thrombolysis or thrombectomy is an option. Decompressive surgery is lifesaving in patients with large venous infarcts or hemorrhage with impending herniation. After the acute phase, patients should anticoagulated for a variable period of time, depending on their inherent thrombotic risk. CVT patients may experience recurrent seizures. Prophylaxis with anti-epileptic drugs is recommended after the first seizure, in those with hemispheric lesions. There are several ongoing multicenter registries and trials, which will improve evidence-based and patient-centered management of CVT in the near future.
Centro Hospitalar Lisboa Norte, University of Lisbon, Instituto de Medicina Molecular, Department of Neurosciences and Mental Health, Serviço de Neurologia, Lisbon, Portugal. Electronic address: jmferro@medicina.ulisboa.pt.
José Manuel
JM
Ferro
Centro Hospitalar Lisboa Norte, University of Lisbon, Instituto de Medicina Molecular, Department of Neurosciences and Mental Health, Serviço de Neurologia, Lisbon, Portugal.
Patrícia
P
Canhão
Centro Hospitalar Lisboa Norte, University of Lisbon, Instituto de Medicina Molecular, Department of Neurosciences and Mental Health, Serviço de Neurologia, Lisbon, Portugal.
Diana
D
Aguiar de Sousa
D006801:Humans; D020767:Intracranial Thrombosis / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D011379:Prognosis; D020246:Venous Thrombosis / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy